Biomarker ID | 984 |
PMID | 22977195 |
Year | 2012 |
Biomarker | PTEN |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Overexpressed for Progression Free Survival |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include: Immune system, Disease, T cell receptor regulation of apoptosis, Adaptive immune system, TGF-beta regulation of extracellular matrix |
Experiment | Progression Free Survival |
Type of Biomarker | Prognostic |
Cohort | Patients with mCRPC progressing during or within 90 days after at least 12 weeks of docetaxel were included in this phase II trial. 27 patients were avaliable for IHC analysis. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p= 0.02 |
Method Used | Immunohistochemistry |
Clinical | Yes |
Remarks | PFS was defined as the absence of disease progression for biochemical PSA progression |
Clinical Trial Number | NCT00728663 |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |